Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Wise-Draper briefly explains the study that Nooshin Hashemi Sadraei, MD, conducted on patients with HNC, as well as the importance of looking at QOL. Sadraei used certified QOL surveys with patients undergoing chemotherapy and radiation. Results from the survey showed correlations with the ending adverse effects.
In future studies, Wise-Draper states that Sadraei plans to use immunotherapies in hopes of reducing the adverse effects and improving QOL.
Trisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More